ImmuneOncia Therapeutics Inc.
Clinical trials sponsored by ImmuneOncia Therapeutics Inc., explained in plain language.
A biotech company developing immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug IMC-001 targets Hard-to-Treat cancers in small trial Results expected Jun 2027 (estimated)
-
New hope for advanced cancer: experimental drug IMC-002 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…
Phase 1 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug IMC-001 targets Hard-to-Treat cancers in small trial
Disease control Recruiting nowThis phase 2 trial tests the drug IMC-001 in 30 adults with advanced solid tumors that have a high number of genetic mutations (TMB-H). Participants receive the drug by IV every two weeks. The main goal is to see if the drug shrinks tumors. Researchers will also monitor side effe…
Phase 2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC